Biotech RadarJobs updated

COMPANY

Olema Oncology

HQ: San Francisco, CA source · olema.com ↗

Clinical Phase 3

23 open jobs · last seen Oct 23, 2026 · 7 sources

Location: San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Metastatic Breast Cancer Breast Cancer ER Positive Breast Cancer Locally Advanced Breast Cancer HER2 Negative Breast Carcinoma HER2-negative Breast Cancer Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) Fulvestrant Palazestrant Advanced Breast Cancer Hormone Receptor Positive Breast Carcinoma OP-3136 OP-1250

23Open jobs6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Director, Commercial Data ScienceBoston, MassachusettsOct 16, 2026Oct 17, 2026
Director, Commercial Data ScienceSan Francisco, CaliforniaOct 16, 2026Oct 17, 2026
Director, Global Regulatory Affairs Strategy LeadSan Francisco, CaliforniaOct 15, 2026Oct 16, 2026
Director, Global Regulatory Affairs - Strategy LeadBoston, MassachusettsOct 15, 2026Oct 16, 2026
Senior Director, Commercial Manufacturing and OperationsSan Francisco, CaliforniaOct 13, 2026Oct 14, 2026

See all 23 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (23 open jobs at last check). source ↗
  2. Trial start Phase 3: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer source ↗
  3. Trial start 1: Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors source ↗
  4. Trial start Phase 3: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer source ↗
  5. Trial start 1: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer source ↗
  6. Trial start 1: A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients source ↗
  7. Trial start Phase 1/Phase 2: A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 23

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Director, Commercial Data ScienceBoston, MassachusettsOct 16, 2026Oct 17, 2026Not stated
Director, Commercial Data ScienceSan Francisco, CaliforniaOct 16, 2026Oct 17, 2026Not stated
Director, Global Regulatory Affairs Strategy LeadSan Francisco, CaliforniaOct 15, 2026Oct 16, 2026Not stated
Director, Global Regulatory Affairs - Strategy LeadBoston, MassachusettsOct 15, 2026Oct 16, 2026Not stated
Senior Director, Commercial Manufacturing and OperationsSan Francisco, CaliforniaOct 13, 2026Oct 14, 2026Senior
Senior Director, Commercial Manufacturing and OperationsBoston, MassachusettsOct 13, 2026Oct 14, 2026Senior
Principal Talent Acquisition PartnerSan Francisco, CaliforniaOct 7, 2026Oct 9, 2026Senior
Medical Director, Clinical DevelopmentBoston, MassachusettsOct 2, 2026Oct 9, 2026Senior
Senior Manager, Clinical Supply IntegrationBoston, MassachusettsSep 29, 2026Oct 9, 2026Senior
Senior Manager, Clinical Supply IntegrationSan Francisco, CaliforniaSep 29, 2026Oct 9, 2026Senior
Senior Director, Patient Safety SciencesBoston, MassachusettsSep 25, 2026Oct 9, 2026Senior
Senior Director, Patient Safety SciencesSan Francisco, CaliforniaSep 25, 2026Oct 9, 2026Senior
Vice President of Information TechnologySan Francisco, CaliforniaSep 22, 2026Oct 9, 2026Executive
Director, Commercial Insights and AnalyticsBoston, MassachusettsSep 2, 2026Oct 9, 2026Senior
Director, Commercial Insights and AnalyticsSan Francisco, CaliforniaSep 2, 2026Oct 9, 2026Senior
Director, CompensationBoston, MassachusettsAug 28, 2026Oct 9, 2026Senior
Associate Director, Global Regulatory Affairs, Compliance and Project ManagementBoston, MassachusettsAug 25, 2026Oct 9, 2026Senior
Associate Director, Global Regulatory Affairs, Compliance and Project ManagementSan Francisco, CaliforniaAug 25, 2026Oct 9, 2026Senior
Director, CompensationSan Francisco, CaliforniaAug 25, 2026Oct 9, 2026Senior
Executive Assistant, supporting Chief Financial OfficerSan Francisco, CaliforniaAug 24, 2026Oct 9, 2026Mid
Senior Director, National and Strategic AccountsRemoteAug 19, 2026Oct 9, 2026Senior
Senior Director, EU Regulatory StrategyDublin, IrelandAug 4, 2026Oct 9, 2026Senior
Medical Science Liaison/Senior Medical Science Liaison (Southeast Region)RemoteJul 2, 2026Oct 9, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06784193Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors1RecruitingDec 16, 2024May 30, 2027 (estimated)
NCT07085767Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3RecruitingNov 3, 20252028-12 (estimated)
NCT05508906Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer1Active, not recruitingAug 31, 2022Dec 31, 2027 (estimated)
NCT06016738OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPhase 3Active, not recruitingNov 16, 2023Oct 31, 2026 (estimated)
NCT04505826A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerPhase 1/Phase 2CompletedAug 13, 2020Jul 30, 2024 (actual)
NCT05266105A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients1Active, not recruitingDec 10, 20212026-03 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Olema Oncology on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback